BioXcel Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . BioXcel Therapeutics
BTAI Stock  USD 2.19  0.09  3.95%   
BioXcel Therapeutics financial statements provide useful quarterly and yearly information to potential BioXcel Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on BioXcel Therapeutics financial statements helps investors assess BioXcel Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting BioXcel Therapeutics' valuation are summarized below:
Gross Profit
251 K
Market Capitalization
7.2 M
Enterprise Value Revenue
31.5515
Revenue
2.3 M
Earnings Share
(32.64)
We have found one hundred twenty available fundamental signals for BioXcel Therapeutics, which can be analyzed and compared to other ratios and to its rivals. Traders should compare all of BioXcel Therapeutics prevailing fundamentals against the fundamentals between 2010 and 2025 to make sure the company is sustainable this year. The current Market Cap is estimated to decrease to about 5.7 B. Enterprise Value is estimated to decrease to about 5.6 B

BioXcel Therapeutics Total Revenue

1.67 Million

Check BioXcel Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioXcel Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 16.1 M, Selling General Administrative of 76.7 M or Total Revenue of 1.7 M, as well as many indicators such as Price To Sales Ratio of 1.1 K, Dividend Yield of 0.0 or Days Sales Outstanding of 20.52. BioXcel financial statements analysis is a perfect complement when working with BioXcel Therapeutics Valuation or Volatility modules.
  
Check out the analysis of BioXcel Therapeutics Correlation against competitors.
For more detail on how to invest in BioXcel Stock please use our How to Invest in BioXcel Therapeutics guide.

BioXcel Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets100.3 M84.8 M62.8 M
Slightly volatile
Total Current Liabilities32.9 M31.4 M10.6 M
Slightly volatile
Common Stock Shares Outstanding21.5 M33.5 M17.2 M
Slightly volatile
Total Liabilities157.2 M149.7 M38.4 M
Slightly volatile
Total Current Assets98.2 M83 M61.5 M
Slightly volatile
Property Plant Equipment855.5 K1.2 M588.3 K
Slightly volatile
Other Current Liabilities8.5 M15.1 M5.4 M
Slightly volatile
Property Plant And Equipment Net1.6 M1.7 M920.1 K
Slightly volatile
Accounts Payable16.5 M15.7 M4.6 M
Slightly volatile
Non Current Assets Total2.3 M1.8 M1.3 M
Slightly volatile
Non Currrent Assets Other95 K100 K363.9 K
Slightly volatile
Liabilities And Stockholders Equity112.8 M84.8 M63.6 M
Slightly volatile
Other Current Assets3.4 M5.6 M2.1 M
Slightly volatile
Property Plant And Equipment Gross1.9 M3.1 M1.2 M
Slightly volatile
Short and Long Term Debt Total122.4 M116.6 M27.7 M
Slightly volatile
Other Assets1.091.15399.9 K
Pretty Stable
Cash And Short Term Investments122.7 M75 M61.6 M
Slightly volatile
Common Stock Total Equity22.7 K32.2 K17.3 K
Slightly volatile
Capital Surpluse589.6 M561.5 M194.7 M
Slightly volatile
Deferred Long Term Liabilities1.5 M2.7 M1.4 M
Slightly volatile
Short and Long Term Debt296.8 K333.9 K364 K
Slightly volatile
Short Term Debt317.2 K397.9 K325.4 K
Slightly volatile
Capital Stock26.4 K34.5 K20.8 K
Slightly volatile
Capital Lease Obligations914.6 K707.4 K1 M
Pretty Stable
Non Current Liabilities Other863.6 K707.4 K996 K
Slightly volatile
Other Liabilities1.9 M2.1 M2.3 M
Slightly volatile
Long Term Debt106.5 M115.7 M95.8 M
Slightly volatile
Long Term Debt Total74.4 M83.7 M91.3 M
Slightly volatile

BioXcel Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative76.7 M73 M23.7 M
Slightly volatile
Other Operating Expenses209.1 M199.1 M62.7 M
Slightly volatile
Research Development101.8 M97 M33.6 M
Slightly volatile
Total Operating Expenses207.6 M197.7 M62.5 M
Slightly volatile
Interest Income7.5 M7.1 M1.6 M
Slightly volatile
Reconciled Depreciation205.4 K369.1 K118 K
Slightly volatile
Non Operating Income Net Other2.5 M2.4 M605.2 K
Slightly volatile
Selling And Marketing Expenses18.1 M22.9 M14.4 M
Slightly volatile

BioXcel Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Capital Expenditures21.9 K23 K157.8 K
Pretty Stable
Total Cash From Financing Activities29 M30.5 M38.2 M
Slightly volatile
Stock Based Compensation10.8 M21.4 M7.2 M
Slightly volatile
Change In Working Capital3.4 M2.3 M2 M
Slightly volatile
Change To Netincome22.4 M21.3 M8 M
Slightly volatile
Change To Liabilities20.3 M19.4 M5.6 M
Slightly volatile
End Period Cash Flow122.7 M75 M61.6 M
Slightly volatile
Issuance Of Capital Stock21.1 M22.2 M61 M
Very volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.1 K1.1 K21.1 K
Slightly volatile
Days Sales Outstanding20.5221.6200
Slightly volatile
Stock Based Compensation To Revenue14.7415.5140.2972
Slightly volatile
Capex To Depreciation0.06870.07233.7236
Slightly volatile
EV To Sales1.1 K1.2 K20.9 K
Slightly volatile
Inventory Turnover0.60.570.1209
Slightly volatile
Days Of Inventory On Hand63066329.6 K
Slightly volatile
Payables Turnover0.08720.08310.0272
Slightly volatile
Sales General And Administrative To Revenue50.2852.93158
Slightly volatile
Research And Ddevelopement To Revenue66.7670.27210
Slightly volatile
Capex To Revenue0.01580.01670.3041
Slightly volatile
Cash Per Share3.742.022.4347
Slightly volatile
Days Payables Outstanding4.3 K4.5 K22 K
Slightly volatile
Income Quality0.560.780.6164
Slightly volatile
Current Ratio2.262.383.7172
Slightly volatile
Receivables Turnover18.3717.494.6846
Slightly volatile
Capex Per Share8.0E-48.0E-40.0087
Pretty Stable
Revenue Per Share0.02430.04260.018
Slightly volatile
Interest Debt Per Share3.723.540.9566
Slightly volatile
Debt To Assets1.31.240.4146
Slightly volatile
Operating Cycle65168529.8 K
Slightly volatile
Days Of Payables Outstanding4.3 K4.5 K22 K
Slightly volatile
Ebt Per Ebit0.80.940.9856
Slightly volatile
Long Term Debt To Capitalization2.162.050.445
Slightly volatile
Quick Ratio2.22.323.7014
Slightly volatile
Net Income Per E B T0.80.930.9754
Pretty Stable
Cash Ratio2.052.153.7784
Slightly volatile
Days Of Inventory Outstanding63066329.6 K
Slightly volatile
Days Of Sales Outstanding20.5221.6200
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.111.151.0236
Slightly volatile
Fixed Asset Turnover0.450.840.2871
Slightly volatile
Debt Ratio1.31.240.4146
Slightly volatile
Price Sales Ratio1.1 K1.1 K21.1 K
Slightly volatile
Asset Turnover0.01770.01690.0048
Slightly volatile
Gross Profit Margin0.0950.10.7868
Slightly volatile

BioXcel Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap5.7 B7.7 B5.8 B
Slightly volatile
Enterprise Value5.6 B7.5 B5.7 B
Slightly volatile

BioXcel Fundamental Market Drivers

Cash And Short Term Investments65.2 M

BioXcel Upcoming Events

14th of March 2024
Upcoming Quarterly Report
View
13th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
14th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About BioXcel Therapeutics Financial Statements

Investors use fundamental indicators, such as BioXcel Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although BioXcel Therapeutics' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Current Deferred Revenue133.4 K126.7 K
Total Revenue1.6 M1.7 M
Cost Of Revenue1.4 M1.5 M
Stock Based Compensation To Revenue 15.51  14.74 
Sales General And Administrative To Revenue 52.93  50.28 
Research And Ddevelopement To Revenue 70.27  66.76 
Capex To Revenue 0.02  0.02 
Revenue Per Share 0.04  0.02 
Ebit Per Revenue(112.03)(117.63)

Currently Active Assets on Macroaxis

VVisa Class A
CRMSalesforce
CRMSalesforce
MSFTMicrosoft
VVisa Class A
When determining whether BioXcel Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BioXcel Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bioxcel Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bioxcel Therapeutics Stock:
How To Invest In BioXcel
Details
Is BioXcel Stock a good investment?
Details
What is BioXcel Therapeutics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of BioXcel Therapeutics Correlation against competitors.
For more detail on how to invest in BioXcel Stock please use our How to Invest in BioXcel Therapeutics guide.
You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioXcel Therapeutics. If investors know BioXcel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioXcel Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(32.64)
Revenue Per Share
1.019
Quarterly Revenue Growth
(0.37)
Return On Assets
(0.62)
Return On Equity
(17.67)
The market value of BioXcel Therapeutics is measured differently than its book value, which is the value of BioXcel that is recorded on the company's balance sheet. Investors also form their own opinion of BioXcel Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is BioXcel Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioXcel Therapeutics' market value can be influenced by many factors that don't directly affect BioXcel Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between BioXcel Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if BioXcel Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioXcel Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY